Progress in BRCA-Mutated Ovarian Cancer

The article by Moore et al.1 in this issue of the Journal is the culmination of a long march for olaparib in the treatment of BRCA-mutated high-grade serous ovarian cancer — one that began with its discovery by means of synthetic lethality screening, followed by years of clinical trials to define its activity and refine its uses, and finally led to its implementation in a population of women with potentially curable ovarian cancer. Olaparib is the first in a wave of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors, a class of agents that is changing primary treatment of ovarian cancer for the . . .